George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBaronsmead 2vt Regulatory News (BMD)

Share Price Information for Baronsmead 2vt (BMD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 55.50
Bid: 54.00
Ask: 57.00
Change: 0.00 (0.00%)
Spread: 3.00 (5.556%)
Open: 55.50
High: 55.50
Low: 55.50
Prev. Close: 55.50
BMD Live PriceLast checked at -
Baronsmead Second Venture Trust is an Investment Trust

To achieve long-term investment returns for private investors by investing primarily in a diverse portfolio of UK growth businesses, whether unquoted or traded on AIM.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Allotment of Shares and Total Voting Rights

15 Feb 2024 14:00

RNS Number : 3206D
Baronsmead Second Venture Trust PLC
15 February 2024

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, THE UNITED STATES OR ANY MEMBER STATE OF THE EEA (OTHER THAN ANY MEMBER STATE OF THE EEA WHERE THE COMPANY'S SECURITIES MAY BE LEGALLY MARKETED), OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT. THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER TO ISSUE OR SELL, OR ANY SOLICITATION OF ANY OFFER TO SUBSCRIBE OR PURCHASE, ANY INVESTMENTS IN ANY JURISDICTION.

BARONSMEAD SECOND VENTURE TRUST PLC

LEI: 2138008D3WUMF6TW8C28

15 February 2024

Allotment of Shares and Total Voting Rights

The Board of Baronsmead Second Venture Trust plc (the "Company") announced on 24 November 2023 that the Company, together with Baronsmead Venture Trust plc, had published a prospectus (the "Prospectus") in relation to offers for subscription to raise up to £30 million in aggregate with the discretion to utilise over-allotment facilities to raise up to a further £20 million in aggregate (the "Offers" and each an "Offer").

On 15 February 2024 and in accordance with the Allotment Formula set out in the Prospectus, the Company allotted 2,413,724 Ordinary Shares of 10 pence each (the "New Ordinary Shares") in the capital of the Company pursuant to the second allotment under the Offer conditional only on Admission (the timetable for which is set out in more detail below). The New Ordinary Shares were issued at prices of between 59.61 pence per New Ordinary Share and 62.83 pence per New Ordinary Share, depending on the amount of Offer Costs, any Initial Commission waived, any Initial Adviser Charges, any Early Bird Discount associated with an Application and based on the net asset value per Ordinary Share as at 31 January 2024 (being the last published net asset value per Ordinary Share as announced on 7 February 2024, adjusted for dividends following the ex-dividend date).

Application will shortly be made for the 2,413,724 New Ordinary Shares to be admitted to the premium segment of the Official List of the Financial Conduct Authority and to trading on the premium segment of London Stock Exchange plc's main market for listed securities ("Admission"). It is expected that Admission will occur and dealing will commence in the New Ordinary Shares on or around 22 February 2024. When issued, the New Ordinary Shares will rank pari passu with the existing Ordinary Shares.

As a result of the issue, the total number of Ordinary Shares in issue will be 372,888,416 (excluding the 36,859,587 Ordinary Shares currently held in Treasury) with each Ordinary Share carrying one vote each. Therefore, the total voting rights in the Company will be 372,888,416. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure Guidance and Transparency Rules.

The New Ordinary Shares will be issued in registered form and may be held in uncertificated form. Definitive documents of title are expected to be dispatched within 10 business days of allotment. The New Ordinary Shares will be eligible for settlement through CREST with effect from Admission.

Unless the context requires otherwise, terms defined in the Prospectus have the same meaning where used in this announcement.

For further information please contact:

Baronsmead VCT Investor Relations

020 7382 0999

baronsmeadvcts@greshamhouse.com

Important Information

This Announcement is an advertisement for the purposes of the Prospectus Regulation Rules of the UK Financial Conduct Authority ("FCA") and is not a prospectus. This Announcement does not constitute or form part of, and should not be construed as, an offer for sale or subscription of, or solicitation of any offer to subscribe for or to acquire, any ordinary shares in Baronsmead Venture Trust plc or Baronsmead Second Venture Trust plc (together the "Companies") in any jurisdiction, including in or into Australia, Canada, Japan, the Republic of South Africa, the United States or any member state of the EEA (other than any member state of the EEA where the Companies' securities may be lawfully marketed). Investors should not subscribe for or purchase any ordinary shares referred to in this Announcement except on the basis of information in the prospectus (the "Prospectus") in its final form, published on 24 November 2023 by Baronsmead Venture Trust plc and Baronsmead Second Venture Trust plc, together with the supplementary prospectus published on 19 January 2024 (the "Supplementary Prospectus"), in connection with the Offer. A copy of the Prospectus and Supplementary Prospectus is available for inspection, subject to certain access restrictions, from the Company's registered office, for viewing at the National Storage Mechanism at https://data.fca.org.uk/#/nsm/nationalstoragemechanism and on the Company's website (http://www.baronsmeadvcts.co.uk). Approval of the Prospectus and Supplementary Prospectus by the FCA should not be understood as an endorsement of the securities that are the subject of the Prospectus and Supplementary Prospectus. Potential investors are recommended to read the Prospectus and Supplementary Prospectus before making an investment decision in order to fully understand the potential risks and rewards associated with a decision to invest in the Companies' securities.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
IOESFIFDIELSELE
Date   Source Headline
3rd Apr 20249:00 amRNSShare Allotment, Total Voting Rights, Offer Close
3rd Apr 20247:00 amRNSTransaction in Own Shares
2nd Apr 20247:00 amRNSClose of Offer to New Applications
20th Mar 20248:02 amRNSCHANGE OF ALLOTMENT DATE & EXTENSION OF THE OFFER
19th Mar 20245:37 pmRNSClose of Offer to New Applications
18th Mar 20244:48 pmRNSDirector/PDMR Shareholding
18th Mar 20244:46 pmRNSDirector/PDMR Shareholding
14th Mar 20241:00 pmRNSIntention to Utilise Over-allotment Facility
6th Mar 20243:00 pmRNSNet Asset Value(s)
6th Mar 20241:46 pmRNSResult of AGM
1st Mar 202410:34 amRNSTotal Voting Rights
15th Feb 20242:00 pmRNSAllotment of Shares and Total Voting Rights
7th Feb 202410:00 amRNSNet Asset Value(s)
2nd Feb 20242:50 pmRNSDirector/PDMR Shareholding
1st Feb 20245:12 pmRNSTotal Voting Rights
1st Feb 20247:00 amRNSTransaction in Own Shares
30th Jan 202412:03 pmRNSDirector/PDMR Shareholding
26th Jan 20242:30 pmRNSAllotment of Shares and Total Voting Rights
24th Jan 20245:00 pmRNSNet Asset Value(s)
24th Jan 20244:00 pmRNSNet Asset Value(s)
22nd Jan 20243:00 pmRNSOffer Update Extension of Early Bird Discount Date
19th Jan 20242:35 pmRNSIssue of Supplementary Prospectus
4th Jan 20243:46 pmRNSChange of allotment date
2nd Jan 202411:00 amRNSTotal Voting Rights
22nd Dec 20237:00 amRNSAnnual Financial Report
12th Dec 20235:46 pmRNSTransaction in Own Shares
6th Dec 20231:30 pmRNSNet Asset Value(s)
24th Nov 20231:26 pmRNSPublication of a Prospectus/Offer for Subscription
22nd Nov 20237:00 amRNSCompliance with Market Abuse Regulation ("MAR")
14th Nov 202310:05 amRNSUpdate on Offer for Subscription
6th Nov 20234:00 pmRNSNet Asset Value(s)
27th Oct 20231:30 pmRNSNet Asset Value(s)
2nd Oct 20234:02 pmRNSTotal Voting Rights
28th Sep 20235:52 pmRNSTransaction in Own Shares
25th Sep 202312:28 pmRNSDirector/PDMR Shareholding
25th Sep 202312:25 pmRNSDirector/PDMR Shareholding
13th Sep 20237:00 amRNSTransaction in Own Shares - Replacement
12th Sep 20235:28 pmRNSTransaction in Own Shares
5th Sep 202311:00 amRNSIntention to Fundraise
4th Aug 20234:00 pmRNSNet Asset Value(s)
1st Aug 20231:54 pmRNSTotal Voting Rights
27th Jul 20234:11 pmRNSTransaction in Own Shares
24th Jul 20232:00 pmRNSNet Asset Value(s)
3rd Jul 202311:25 amRNSTotal Voting Rights
20th Jun 20233:40 pmRNSTransaction in Own Shares
13th Jun 20237:00 amRNSHalf-yearly Report
6th Jun 20235:30 pmRNSNet Asset Value(s)
12th May 20237:00 amRNSCompliance with the Market Abuse Regulation
5th May 20235:30 pmRNSNet Asset Value(s)
4th May 20231:00 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.